Drugs / GPI 1485
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00076492 | Jan 2004 → Sep 2005 | Parkinson disease | University of Rochester | Completed | No outcome recorded |
| Phase 2 | NCT00090376 | Dec 2003 → ? | erectile dysfunction, prostate cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00209508 | Nov 2002 → Oct 2005 | Parkinson disease | Eisai Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GPI 1485 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00209508 ↗ |
| Modality | Small molecule | — CHEMBL4297382 ↗ |
| Route | Oral | “GPI 1485 will be supplied as an oral tablet formulation” NCT00090376 ↗ |